Home | Contact Us | Site Map
Dhtml Menu Css by Vista-Buttons.com v5.7
 
Mucosal Vaccine Pipeline

Universal Adjuvant & Antigen Delivery System:

NanoBio's nanoemulsion-based, intranasal vaccines have elicited robust immune responses in animals vaccinated against influenza, RSV, urinary tract infection, pneumococcal disease, hepatitis B, RSV, anthrax, smallpox, cancer and other diseases.  In some cases, the immune response is exponentially higher than what is required to provide adequate protection against infection. 

The nanoemulsion is uniquely capable of permeating the nasal mucosa, where it loads vaccine antigen into immune-presenting cells. These cells then carry the antigen to areas of the body that initiate an immune response, including the lymph nodes, thymus and spleen producing both mucosal immunity and systemic immune response. 

Mechanism of Action:


Click here for larger view

Significant advantages of NanoBio's universal adjuvant & antigen delivery system:

  • Nasal delivery presents the antigen where it can most directly access the immune system
  • Induces robust mucosal immunity and a systemic Th1 cellular as well as a humoral response that protects against subsequent disease challenge
  • Cross protection
  • Adjuvants multiple antigen types
  • Non-inflammatory
  • Antigen-sparing
  • Thermally stable, requires no refrigeration
  • Needle-free, easy to administer
  • Inexpensive manufacturing

BlueLine

© NanoBio® Corporation 2010
NanoBio is a registered trademark of NanoBio Corporation.
All other company, brand, and product names are or may be trademarks of their respective holders. Website by Mellon & Associates, LLC.